查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球CT/NG檢測市場：按產品（檢測/試劑盒,分析儀）,檢測類型（實驗室,PoC 檢測）,技術（INAAT,PCR,免疫診斷）,最終用戶（診斷實驗室,醫院/診所）,地區預測到2028
市場調查報告書
商品編碼
1306575

全球CT/NG檢測市場：按產品（檢測/試劑盒,分析儀）,檢測類型（實驗室,PoC 檢測）,技術（INAAT,PCR,免疫診斷）,最終用戶（診斷實驗室,醫院/診所）,地區預測到2028

CT/NG Testing Market by Product (Assays, Kits & Analyzers), Test Type (Laboratory, Point-of-care Testing), Technology (INAAT, PCR, Immunodiagnostics), End User (Diagnostic Labs, Hospitals & Clinics) & Region - Global Forecast to 2028
出版日期: | 出版商: MarketsandMarkets | 英文 182 Pages | 訂單完成後即時交付

價格
簡介目錄

全球 CT/NG 檢查市場規模預計將從 2023 年的 17 億美元增至 2028 年的 27 億美元，預測期內復合年增長率為 8.6%。

CT/NG 感染（沙眼衣原體/淋病）患病率的上升,CT/NG 的穩定投資和資金以及 CT/NG 診斷意識的不斷增強是推動該市場增長的因素。 然而，CT/NG檢查設備和套件的高價格以及技術人員的短缺可能會阻礙CT/NG檢查市場的增長。

“檢測試劑盒細分市場將在預測期內佔據最高的市場份額”

按產品劃分，檢測試劑盒細分市場將在 2022 年佔據 CT/NG 檢測市場的最大份額。 該領域增長的原因是與疾病診斷設備相比，對檢測試劑盒的需求強勁且持續。 由於高重複率，持續購買檢測試劑盒直接影響該產品領域的規模和高增長率。

“INAAT 將在預測期內實現最高增長”

從技術角度來看，INAAT領域將在2022年佔據CT/NG檢查市場的最大份額。 INAAT領域的巨大份額歸因於多種因素，包括CT/NG患病率的上升,INAAT的成本效益,INAAT的周轉時間,對高精度和快速診斷的需求以及輸血和獻血的增加。

“亞太地區：CT/NG 檢查市場增長最快的地區”

按地區劃分，亞太地區預計在預測期內復合年增長率最高。 該地區的新興經濟體的國內生產總值正在增長，可支配收入水平也在不斷上升。 結果，醫療費用不斷增加，醫療基礎設施不斷現代化，臨床檢測技術越來越普及。 這些因素預計將為在該地區運營的 CT/NG 檢查公司提供重大增長機會。

內容

第一章簡介

第 2 章研究方法

第 3 章執行摘要

第 4 章重要考慮因素

第五章市場概述

  • 簡介
  • 市場動態
    • 驅動程序
    • 制約因素
    • 機會
    • 任務
  • 價格分析
  • 專利分析
  • 價值鏈分析
  • 供應鏈分析
  • 生態系統/市場地圖
  • 波特五力分析
  • 監管分析
  • 貿易分析
  • 杵分析
  • 技術分析
  • 重大會議和活動（2023-2024 年）
  • 影響客戶業務的趨勢/干擾
  • 主要利益相關者和採購標準

第 6 章 CT/NG 檢驗市場：按產品

  • 簡介
  • 檢測試劑盒
  • 設備/分析設備

第 7 章 CT/NG 檢驗市場：按測試類型

  • 簡介
  • 實驗室測試
  • PoC（護理點）檢查

第 8 章 CT/NG 檢測市場：按技術

  • 簡介
  • PCR（聚合□鍊式反應）
  • INAAT（等溫核酸擴增技術）
  • 免疫診斷
  • 其他技術

第 9 章 CT/NG 檢驗市場：按最終用戶劃分

  • 簡介
  • 診斷實驗室
  • 醫院和診所
  • 其他最終用戶

第 10 章 CT/NG 檢驗市場：按地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 亞太地區其他地區
  • 拉丁美洲
  • 中東和非洲

第 11 章競爭格局

  • 概述
  • 主要公司的戰略
  • 頂級公司的收入份額分析
  • 市場份額分析
  • 企業評估矩陣（2022 年）
  • 業務評估矩陣：初創企業/中小企業 (2022 年)
  • 競爭基準測試
  • 競爭場景

第12章公司簡介

  • 主要公司
    • F. HOFFMANN-LA ROCHE LTD
    • HOLOGIC, INC.
    • THERMO FISHER SCIENTIFIC, INC.
    • ABBOTT LABORATORIES
    • PERKINELMER, INC.
    • QIAGEN
    • SIEMENS HEALTHINEERS AG
    • DANAHER
    • BECTON, DICKINSON AND COMPANY
    • BIO-RAD LABORATORIES, INC.
  • 其他企業
    • SEEGENE, INC.
    • MERIDIAN BIOSCIENCE
    • GENETIC SIGNATURES
    • ELITECHGROUP
    • MOLBIO DIAGNOSTICS PVT. LTD.
    • BINX HEALTH, INC.
    • VISBY MEDICAL, INC.
    • GENEPROOF A.S.
    • BIONEER CORPORATION
    • MICROBIOLOGICS
    • SANSURE BIOTECH, INC.
    • VIRCELL
    • OPERON
    • TIANLONG
    • GOFFIN MOLECULAR TECHNOLOGIES

第13章 附錄

簡介目錄
Product Code: MD 8707

The global CT/NG testing market is projected to reach USD 2.7 billion by 2028 from USD 1.7 billion in 2023, at a CAGR of 8.6% during the forecast period. Increasing prevalence of CT/NG infections, steady investments and funds in CT/NG and rising attempts in awareness for CT/NG diagnosis are factors driving the growth of this market. However high prices of CT/NG testing instruments and kits along with scarcity in technicians is likely to hamper the growth of CT/NG testing market.

"The assays and kits segment accounted for the highest market share during the forecast period"

Based on product, the global CT/NG testing market is segmented into two segments namely, assays & kits and instruments/analyzers. In 2022, the assays & kits segment accounted for the largest share of the CT/NG testing market. The rising growth of this segment is due to the continuous and high demand of assays & kits in comparison to instruments for diagnosis of the disease. The continuous purchase of assay & kits makes them a high recurring purchase which then directly influences the large size and high growth rate of this product segment.

"INAAT accounted for the highest growth during the forecast period"

Based on technology, the CT/NG testing market is broadly segmented into INAAT (isothermal nucleic acid amplification technology), PCR (polymerase chain reaction), immunodiagnostics and other technologies. In 2022, the INAAT (isothermal nucleic acid amplification technology) segment held the dominant position in the CT/NG testing market, representing the largest share. The large share of the INAAT segment can be attributed to several factors such as such as the rising prevalence of CT/NG, the cost benefits of INAAT, turnaround time of INAAT, the need for prompt diagnosis with high accuracy, and the increasing number of blood transfusions and donations.

"Asia Pacific: The fastest-growing region CT/NG testing market"

Based on the region segmentation, the CT/NG testing market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Emerging countries in this region have witnessed growth in their GDPs and a rise in disposable income levels. All this leading to increased healthcare spending, healthcare infrastructure modernization, and the rising penetration of clinical laboratory technologies in the Asia Pacific countries. These factors are expected to provide significant growth opportunities for CT/NG testing companies operating in this region.

Breakdown of supply-side primary interviews, by company type, designation, and region:

  • By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
  • By Designation: C-level (27%), Director-level (18%), and Others (55%)
  • By Region: North America (51%), Europe (21%), Asia- Pacific (18%), Latin America (6%) and Middle East & Africa(4%)

Prominent companies include F. Hoffmann-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), QIAGEN (Netherlands), PerkinElmer Inc. (US), Bio-Rad Laboratories, Inc. (US), Siemens Healthineers AG (Germany), Danaher (US), Becton, Dickinson and Company (US), Seegene, Inc. (South Korea), Meridian Bioscience Inc. (US), Binx Health, Inc. (US), Visby Medical, Inc. (US), Geneproof A.S. (Czech Republic), Bioneer Corporation (South Korea), Genetic Signatures (Australia), Microbiologics, Inc. (US), Vircell S.L. (Spain), Sansure Biotech Inc. (China), ELITechGroup (France), Molbio Diagnostics Pvt. Ltd. (India), Operon S.A. (Spain), Tianlong Technology Co., Ltd. (China), and Goffin Molecular Technologies B.V. (Netherlands).

Research Coverage

This research report categorizes the CT/NG testing market by product, testing type, technology, end user, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the CT/NG testing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the CT/NG testing market. Competitive analysis of upcoming startups in the CT/NG testing market ecosystem is covered in this report.

Key Benefits of Buying the Report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall CT/NG testing market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

  • Analysis of key drivers, restraints, opportunities, and challenges influencing the growth of the CT/NG testing market
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the CT/NG testing market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the CT/NG testing market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the CT/NG testing market
  • Competitive Assessment: In-depth assessment of market ranking, growth strategies, and service offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), among others in the CT/NG testing market strategies.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 GEOGRAPHIC SCOPE
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 RESEARCH APPROACH
    • FIGURE 1 CT/NG TESTING MARKET: RESEARCH DESIGN
    • 2.2.1 SECONDARY DATA
      • 2.2.1.1 Key data from secondary sources
    • 2.2.2 PRIMARY DATA
      • 2.2.2.1 Primary sources
      • 2.2.2.2 Key data from primary sources
      • 2.2.2.3 Key industry insights
      • 2.2.2.4 Breakdown of primary interviews
    • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.3 MARKET SIZE ESTIMATION
    • 2.3.1 BOTTOM-UP APPROACH
      • 2.3.1.1 Approach 1: Company revenue estimation approach
    • FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
      • 2.3.1.2 Approach 2: Presentations of companies and primary interviews
      • 2.3.1.3 Growth forecast
      • 2.3.1.4 CAGR projections
    • FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • 2.3.2 TOP-DOWN APPROACH
    • FIGURE 6 CT/NG TESTING MARKET: TOP-DOWN APPROACH
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 7 DATA TRIANGULATION METHODOLOGY
  • 2.5 MARKET SHARE ANALYSIS
  • 2.6 STUDY ASSUMPTIONS
  • 2.7 GROWTH RATE ASSUMPTIONS
  • 2.8 RISK ASSESSMENT
    • 2.8.1 CT/NG TESTING MARKET: RISK ASSESSMENT
  • 2.9 RECESSION IMPACT

3 EXECUTIVE SUMMARY

    • FIGURE 8 CT/NG TESTING MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
    • FIGURE 9 CT/NG TESTING MARKET, BY TESTING TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 10 CT/NG TESTING MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
    • FIGURE 11 CT/NG TESTING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 12 CT/NG TESTING MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)

4 PREMIUM INSIGHTS

  • 4.1 CT/NG TESTING MARKET OVERVIEW
    • FIGURE 13 INCREASING PREVALENCE OF CT/NG INFECTIONS TO DRIVE MARKET
  • 4.2 CT/NG TESTING MARKET, BY PRODUCT, 2023 VS. 2028
    • FIGURE 14 ASSAYS AND KITS SEGMENT TO DOMINATE CT/NG TESTING MARKET IN 2028
  • 4.3 CT/NG TESTING MARKET, BY TESTING TYPE, 2023 VS. 2028
    • FIGURE 15 LABORATORY TESTING SEGMENT TO DOMINATE MARKET IN 2028
  • 4.4 CT/NG TESTING MARKET, BY TECHNOLOGY, 2023 VS. 2028
    • FIGURE 16 PCR SEGMENT TO DOMINATE CT/NG TESTING MARKET DURING STUDY PERIOD
  • 4.5 CT/NG TESTING MARKET, BY END USER, 2023 VS. 2028
    • FIGURE 17 DIAGNOSTIC LABORATORIES SEGMENT TO DOMINATE MARKET IN 2028
  • 4.6 CT/NG TESTING MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
    • FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN CT/NG TESTING MARKET DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 19 CT/NG TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing prevalence of CT/NG infections
      • 5.2.1.2 Increasing investments and initiatives in CT/NG
      • 5.2.1.3 Growing awareness of early disease diagnosis in emerging economies
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Unfavorable reimbursement scenario for diagnostic companies
      • 5.2.2.2 High cost of instruments and lack of budget for small laboratories and physicians' offices
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growth opportunities in emerging economies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Changing regulatory landscape in European Union and US
      • 5.2.4.2 Operational barriers and shortage of skilled laboratory technicians
  • 5.3 PRICING ANALYSIS
    • TABLE 1 AVERAGE SELLING PRICE OF CT/NG TESTING PRODUCTS (2023)
  • 5.4 PATENT ANALYSIS
    • FIGURE 20 PATENT ANALYSIS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES (JANUARY 2013-DECEMBER 2022)
    • 5.4.1 LIST OF KEY PATENTS
  • 5.5 VALUE CHAIN ANALYSIS
    • FIGURE 21 VALUE CHAIN ANALYSIS OF CT/NG TESTING MARKET: MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASES
  • 5.6 SUPPLY CHAIN ANALYSIS
    • FIGURE 22 CT/NG TESTING MARKET: SUPPLY CHAIN ANALYSIS
  • 5.7 ECOSYSTEM MARKET MAP
    • FIGURE 23 CT/NG TESTING MARKET: ECOSYSTEM MARKET MAP
    • 5.7.1 CT/NG TESTING MARKET: ROLE IN ECOSYSTEM
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 2 CT/NG TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.8.1 THREAT OF NEW ENTRANTS
    • 5.8.2 THREAT OF SUBSTITUTES
    • 5.8.3 BARGAINING POWER OF BUYERS
    • 5.8.4 BARGAINING POWER OF SUPPLIERS
    • 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.9 REGULATORY ANALYSIS
    • TABLE 3 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 4 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 5 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 6 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.9.1 NORTH AMERICA
      • 5.9.1.1 US
      • 5.9.1.2 Canada
    • 5.9.2 EUROPE
    • TABLE 7 EUROPE: CLASSIFICATION OF DEVICES
    • 5.9.3 ASIA PACIFIC
      • 5.9.3.1 China
      • 5.9.3.2 Japan
    • TABLE 8 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
      • 5.9.3.3 India
    • 5.9.4 LATIN AMERICA
      • 5.9.4.1 Brazil
      • 5.9.4.2 Mexico
    • 5.9.5 MIDDLE EAST
    • 5.9.6 AFRICA
  • 5.10 TRADE ANALYSIS
    • 5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
    • TABLE 9 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 10 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018-2022 (USD MILLION)
  • 5.11 PESTLE ANALYSIS
  • 5.12 TECHNOLOGY ANALYSIS
  • 5.13 KEY CONFERENCES AND EVENTS IN 2023-2024
    • TABLE 11 CT/NG TESTING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS IN 2023-2024
  • 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • 5.14.1 REVENUE SHIFT AND REVENUE POCKETS FOR CT/NG TESTING PRODUCT MANUFACTURERS
    • 5.14.2 REVENUE SHIFT IN CT/NG TESTING MARKET
  • 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CT/NG TESTING PRODUCTS
    • TABLE 12 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CT/NG TESTING PRODUCTS
    • 5.15.2 BUYING CRITERIA
    • FIGURE 25 KEY BUYING CRITERIA FOR CT/NG TESTING PRODUCTS
    • TABLE 13 KEY BUYING CRITERIA FOR CT/NG TESTING PRODUCTS

6 CT/NG TESTING MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
    • TABLE 14 CT/NG TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • 6.2 ASSAYS AND KITS
    • 6.2.1 RECURRENT REQUIREMENT AND PURCHASE OF ASSAYS AND KITS TO DRIVE GROWTH
    • TABLE 15 KEY ASSAYS AND KITS OFFERED BY MARKET PLAYERS
    • TABLE 16 CT/NG TESTING MARKET FOR ASSAYS AND KITS, BY REGION, 2021-2028 (USD MILLION)
  • 6.3 INSTRUMENTS/ANALYZERS
    • 6.3.1 INCREASING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS TO BOOST GROWTH
    • TABLE 17 KEY INSTRUMENTS/ANALYZERS OFFERED BY MARKET PLAYERS
    • TABLE 18 CT/NG TESTING MARKET FOR INSTRUMENTS/ANALYZERS, BY REGION, 2021-2028 (USD MILLION)

7 CT/NG TESTING MARKET, BY TESTING TYPE

  • 7.1 INTRODUCTION
    • TABLE 19 CT/NG TESTING MARKET, BY TESTING TYPE, 2021-2028 (USD MILLION)
  • 7.2 LABORATORY TESTING
    • 7.2.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND INCREASING FOCUS ON EARLY DISEASE DETECTION TO DRIVE GROWTH
    • TABLE 20 CT/NG TESTING MARKET FOR LABORATORY TESTING, BY REGION, 2021-2028 (USD MILLION)
  • 7.3 POINT-OF-CARE TESTING
    • 7.3.1 FASTER TURNAROUND TIME TO DRIVE GROWTH
    • TABLE 21 CT/NG TESTING MARKET FOR POINT-OF-CARE TESTING, BY REGION, 2021-2028 (USD MILLION)

8 CT/NG TESTING MARKET, BY TECHNOLOGY

  • 8.1 INTRODUCTION
    • TABLE 22 CT/NG TESTING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • 8.2 PCR
    • 8.2.1 GROWING USE OF PCR IN PROTEOMICS AND GENOMICS TO DRIVE GROWTH
    • TABLE 23 CT/NG TESTING MARKET FOR PCR, BY REGION, 2021-2028 (USD MILLION)
  • 8.3 INAAT
    • 8.3.1 COST-BENEFITS OF INAAT TO DRIVE GROWTH
    • TABLE 24 CT/NG TESTING MARKET FOR INAAT, BY REGION, 2021-2028 (USD MILLION)
  • 8.4 IMMUNODIAGNOSTICS
    • 8.4.1 RISING PREVALENCE OF CT/NG AND DEMAND FOR RAPID DIAGNOSTIC KITS TO DRIVE GROWTH
    • TABLE 25 CT/NG TESTING MARKET FOR IMMUNODIAGNOSTICS, BY REGION, 2021-2028 (USD MILLION)
  • 8.5 OTHER TECHNOLOGIES
    • TABLE 26 CT/NG TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021-2028 (USD MILLION)

9 CT/NG TESTING MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 27 CT/NG TESTING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.2 DIAGNOSTIC LABORATORIES
    • 9.2.1 AVAILABILITY OF WIDE RANGE OF TEST PANELS FOR DISEASE TESTING TO SUPPORT GROWTH
    • TABLE 28 CT/NG TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021-2028 (USD MILLION)
  • 9.3 HOSPITALS AND CLINICS
    • 9.3.1 INCREASING NUMBER OF HOSPITALS TO DRIVE GROWTH
    • TABLE 29 CT/NG TESTING MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021-2028 (USD MILLION)
  • 9.4 OTHER END USERS
    • TABLE 30 CT/NG TESTING MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION)

10 CT/NG TESTING MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 31 CT/NG TESTING MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 26 NORTH AMERICA: CT/NG TESTING MARKET SNAPSHOT
    • TABLE 32 NORTH AMERICA: CT/NG TESTING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 33 NORTH AMERICA: CT/NG TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 34 NORTH AMERICA: CT/NG TESTING MARKET, BY TESTING TYPE, 2021-2028 (USD MILLION)
    • TABLE 35 NORTH AMERICA: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 36 NORTH AMERICA: CT/NG TESTING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.2.1 RECESSION IMPACT: NORTH AMERICA
    • 10.2.2 US
      • 10.2.2.1 Growing prevalence of infectious diseases to drive market
    • TABLE 37 US: CT/NG TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 38 US: CT/NG TESTING MARKET, BY TESTING TYPE, 2021-2028 (USD MILLION)
    • TABLE 39 US: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 40 US: CT/NG TESTING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.2.3 CANADA
      • 10.2.3.1 Rising government initiatives to propel market growth in coming years
    • TABLE 41 CANADA: CT/NG TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 42 CANADA: CT/NG TESTING MARKET, BY TESTING TYPE, 2021-2028 (USD MILLION)
    • TABLE 43 CANADA: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 44 CANADA: CT/NG TESTING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.3 EUROPE
    • TABLE 45 EUROPE: CT/NG TESTING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 46 EUROPE: CT/NG TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 47 EUROPE: CT/NG TESTING MARKET, BY TESTING TYPE, 2021-2028 (USD MILLION)
    • TABLE 48 EUROPE: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 49 EUROPE: CT/NG TESTING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.1 RECESSION IMPACT: EUROPE
    • 10.3.2 GERMANY
      • 10.3.2.1 Increasing healthcare expenditure to drive market growth
    • TABLE 50 GERMANY: CT/NG TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 51 GERMANY: CT/NG TESTING MARKET, BY TESTING TYPE, 2021-2028 (USD MILLION)
    • TABLE 52 GERMANY: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 53 GERMANY: CT/NG TESTING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.3 UK
      • 10.3.3.1 Growing number of accredited diagnostic laboratories to propel market growth
    • TABLE 54 UK: CT/NG TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 55 UK: CT/NG TESTING MARKET, BY TESTING TYPE, 2021-2028 (USD MILLION)
    • TABLE 56 UK: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 57 UK: CT/NG TESTING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.4 FRANCE
      • 10.3.4.1 Rising R&D expenditure in France to drive market growth
    • TABLE 58 FRANCE: CT/NG TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 59 FRANCE: CT/NG TESTING MARKET, BY TESTING TYPE, 2021-2028 (USD MILLION)
    • TABLE 60 FRANCE: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 61 FRANCE: CT/NG TESTING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.5 ITALY
      • 10.3.5.1 Adoption of advanced diagnostic technologies to favor growth
    • TABLE 62 ITALY: CT/NG TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 63 ITALY: CT/NG TESTING MARKET, BY TESTING TYPE, 2021-2028 (USD MILLION)
    • TABLE 64 ITALY: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 65 ITALY: CT/NG TESTING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.6 SPAIN
      • 10.3.6.1 Growing demand for diagnostic testing in Spain to favor market growth
    • TABLE 66 SPAIN: CT/NG TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 67 SPAIN: CT/NG TESTING MARKET, BY TESTING TYPE, 2021-2028 (USD MILLION)
    • TABLE 68 SPAIN: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 69 SPAIN: CT/NG TESTING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.7 REST OF EUROPE
    • TABLE 70 REST OF EUROPE: CT/NG TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 71 REST OF EUROPE: CT/NG TESTING MARKET, BY TESTING TYPE, 2021-2028 (USD MILLION)
    • TABLE 72 REST OF EUROPE: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 73 REST OF EUROPE: CT/NG TESTING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 27 ASIA PACIFIC: CT/NG TESTING MARKET SNAPSHOT
    • TABLE 74 ASIA PACIFIC: CT/NG TESTING MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 75 ASIA PACIFIC: CT/NG TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 76 ASIA PACIFIC: CT/NG TESTING MARKET, BY TESTING TYPE, 2021-2028 (USD MILLION)
    • TABLE 77 ASIA PACIFIC: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 78 ASIA PACIFIC: CT/NG TESTING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.1 RECESSION IMPACT: ASIA PACIFIC
    • 10.4.2 CHINA
      • 10.4.2.1 Growing public access to modern healthcare to drive market growth
    • TABLE 79 CHINA: CT/NG TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 80 CHINA: CT/NG TESTING MARKET, BY TESTING TYPE, 2021-2028 (USD MILLION)
    • TABLE 81 CHINA: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 82 CHINA: CT/NG TESTING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.3 JAPAN
      • 10.4.3.1 Universal healthcare reimbursement policy to drive market growth in Japan
    • TABLE 83 JAPAN: CT/NG TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 84 JAPAN: CT/NG TESTING MARKET, BY TESTING TYPE, 2021-2028 (USD MILLION)
    • TABLE 85 JAPAN: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 86 JAPAN: CT/NG TESTING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.4 INDIA
      • 10.4.4.1 Increasing private and public investments in country's healthcare system to drive market growth
    • TABLE 87 INDIA: CT/NG TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 88 INDIA: CT/NG TESTING MARKET, BY TESTING TYPE, 2021-2028 (USD MILLION)
    • TABLE 89 INDIA: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 90 INDIA: CT/NG TESTING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.5 REST OF ASIA PACIFIC
    • TABLE 91 REST OF ASIA PACIFIC: CT/NG TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 92 REST OF ASIA PACIFIC: CT/NG TESTING MARKET, BY TESTING TYPE, 2021-2028 (USD MILLION)
    • TABLE 93 REST OF ASIA PACIFIC: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 94 REST OF ASIA PACIFIC: CT/NG TESTING MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.5 LATIN AMERICA
    • 10.5.1 IMPROVING HEALTHCARE INFRASTRUCTURE TO DRIVE GROWTH OF CT/NG TESTING MARKET IN LATIN AMERICA
    • TABLE 95 LATIN AMERICA: CT/NG TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 96 LATIN AMERICA: CT/NG TESTING MARKET, BY TESTING TYPE, 2021-2028 (USD MILLION)
    • TABLE 97 LATIN AMERICA: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 98 LATIN AMERICA: CT/NG TESTING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.5.2 RECESSION IMPACT: LATIN AMERICA
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 LACK OF SKILLED RESOURCES TO RESTRICT MARKET GROWTH
    • TABLE 99 MIDDLE EAST & AFRICA: CT/NG TESTING MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 100 MIDDLE EAST & AFRICA: CT/NG TESTING MARKET, BY TESTING TYPE, 2021-2028 (USD MILLION)
    • TABLE 101 MIDDLE EAST & AFRICA: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 102 MIDDLE EAST & AFRICA: CT/NG TESTING MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.6.2 RECESSION IMPACT: MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 STRATEGIES OF KEY PLAYERS
    • 11.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN CT/NG TESTING MARKET
    • TABLE 103 OVERVIEW OF STRATEGIES DEPLOYED BY KEY CT/NG TESTING PRODUCTS MANUFACTURING COMPANIES
  • 11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
    • FIGURE 28 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN CT/NG TESTING MARKET
  • 11.4 MARKET SHARE ANALYSIS
    • 11.4.1 CT/NG TESTING MARKET
    • FIGURE 29 CT/NG TESTING MARKET SHARE, BY KEY PLAYER (2022)
    • TABLE 104 CT/NG TESTING MARKET: DEGREE OF COMPETITION
  • 11.5 COMPANY EVALUATION MATRIX, 2022
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • FIGURE 30 CT/NG TESTING MARKET: COMPANY EVALUATION MATRIX, 2022
  • 11.6 COMPANY EVALUATION MATRIX FOR START-UPS/SMES (2022)
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 STARTING BLOCKS
    • 11.6.3 RESPONSIVE COMPANIES
    • 11.6.4 DYNAMIC COMPANIES
    • FIGURE 31 CT/NG TESTING MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022
  • 11.7 COMPETITIVE BENCHMARKING
    • 11.7.1 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS
    • FIGURE 32 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS
    • TABLE 105 CT/NG TESTING MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS
    • TABLE 106 PRODUCT FOOTPRINT OF COMPANIES
    • TABLE 107 REGIONAL FOOTPRINT OF COMPANIES
    • TABLE 108 CT/NG TESTING MARKET: DETAILED LIST OF KEY START-UPS/SMES
  • 11.8 COMPETITIVE SCENARIO
    • 11.8.1 PRODUCT LAUNCHES
    • TABLE 109 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS
    • 11.8.2 DEALS
    • TABLE 110 KEY DEALS

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 12.1.1 F. HOFFMANN-LA ROCHE LTD
    • TABLE 111 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
    • FIGURE 33 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
    • 12.1.2 HOLOGIC, INC.
    • TABLE 112 HOLOGIC, INC.: BUSINESS OVERVIEW
    • FIGURE 34 HOLOGIC, INC.: COMPANY SNAPSHOT (2022)
    • 12.1.3 THERMO FISHER SCIENTIFIC, INC.
    • TABLE 113 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
    • FIGURE 35 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022)
    • 12.1.4 ABBOTT LABORATORIES
    • TABLE 114 ABBOTT LABORATORIES: BUSINESS OVERVIEW
    • FIGURE 36 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)
    • 12.1.5 PERKINELMER, INC.
    • TABLE 115 PERKINELMER, INC.: BUSINESS OVERVIEW
    • FIGURE 37 PERKINELMER, INC.: COMPANY SNAPSHOT (2022)
    • 12.1.6 QIAGEN
    • TABLE 116 QIAGEN: BUSINESS OVERVIEW
    • FIGURE 38 QIAGEN: COMPANY SNAPSHOT (2022)
    • 12.1.7 SIEMENS HEALTHINEERS AG
    • TABLE 117 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW
    • FIGURE 39 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)
    • 12.1.8 DANAHER
    • TABLE 118 DANAHER: BUSINESS OVERVIEW
    • FIGURE 40 DANAHER: COMPANY SNAPSHOT (2022)
    • 12.1.9 BECTON, DICKINSON AND COMPANY
    • TABLE 119 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
    • FIGURE 41 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
    • 12.1.10 BIO-RAD LABORATORIES, INC.
    • TABLE 120 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
    • FIGURE 42 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2022)
  • 12.2 OTHER PLAYERS
    • 12.2.1 SEEGENE, INC.
    • 12.2.2 MERIDIAN BIOSCIENCE
    • 12.2.3 GENETIC SIGNATURES
    • 12.2.4 ELITECHGROUP
    • 12.2.5 MOLBIO DIAGNOSTICS PVT. LTD.
    • 12.2.6 BINX HEALTH, INC.
    • 12.2.7 VISBY MEDICAL, INC.
    • 12.2.8 GENEPROOF A.S.
    • 12.2.9 BIONEER CORPORATION
    • 12.2.10 MICROBIOLOGICS
    • 12.2.11 SANSURE BIOTECH, INC.
    • 12.2.12 VIRCELL
    • 12.2.13 OPERON
    • 12.2.14 TIANLONG
    • 12.2.15 GOFFIN MOLECULAR TECHNOLOGIES
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS